Prudential Financial’s Black Diamond Therapeutics BDTX Stock Holding History

Prudential Financial’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,150	Closed	-$36.5K	–	2498
2026 Q1	$36.5K	Buy	17,150 +4,300	+33%	+$10.2K	﹤0.01%	2343
2025 Q4	$31.2K	Sell	12,850 -250	-2%	-$885	﹤0.01%	2177
2025 Q3	$49.6K	Hold	13,100	–	–	﹤0.01%	2335
2025 Q2	$32.5K	Buy	+13,100	New	+$25.2K	﹤0.01%	2371
2021 Q1	–	Sell	-37,490	Closed	-$1.2M	–	2492
2020 Q4	$1.2M	Buy	37,490 +16,350	+77%	+$537K	﹤0.01%	1664
2020 Q3	$639K	Buy	21,140 +180	+0.9%	+$5.48K	﹤0.01%	1860
2020 Q2	$883K	Buy	20,960 +50	+0.2%	+$1.84K	﹤0.01%	1703
2020 Q1	$522K	Buy	+20,910	New	+$636K	﹤0.01%	1898

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Prudential Financial's BDTX Position: Q2 2026 in Review

Prudential Financial sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 17,150 shares — an estimated $36.5K sold.

Prudential Financial first reported a position in BDTX in Q1 2020 and held it in 8 quarters. The position peaked at $1.2M in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Prudential Financial reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
Prudential Financial sold 17,150 Black Diamond Therapeutics shares in Q2 2026, an estimated $36.5K.
Prudential Financial first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 8 quarters.
Prudential Financial's Black Diamond Therapeutics position peaked at $1.2M in Q4 2020.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.